WHO QualityRights is an initiative which aims to improve the quality of care in mental health and related services and to promote the human rights of people with psychosocial, intellectual and cognitive disabilities, throughout the world.
This training and guidance module addresses the use of coercive and violent practices in mental health and related services with a particular focus on seclusion and restraint. It aims to promote a greater understanding of why these practices are used and build practical skills to help end these prac...tices. While the module itself focuses on ending these practices in the health care setting, much of the content can also be applied in other settings where seclusion and restraint occur, for example in the home and in the wider community.
more
This document provides training and guidance on the reasons for, and the impact of, violence, coercion and abuse within mental health and related settings. It also provides guidance on how to implement strategies to end the use of coercion, violence and abuse in these settings.
Review
Triccas and Counoupas Pneumonia (2016) 8:18; DOI 10.1186/s41479-016-0020-z
Towards ending tuberculosis and multidrug-resistant tuberculosis.
PLOS ONE | DOI:10.1371/journal.pone.0155525 May 19, 2016, 1 / 11
Eur Respir J 2016; 48: 808–817 | DOI: 10.1183/13993003.00840-2016
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more